Cargando…

Efficacy and tolerability of a gatifloxacin/prednisolone acetate fixed combination for topical prophylaxis and control of inflammation in phacoemulsification: a 20-day-double-blind comparison to its individual components

OBJECTIVE: To compare the efficacy and tolerability of a fixed combination of 0.3% gatifloxacin and 1% prednisolone (Zypred®) versus the individual components used separately (Zymar® and Predfort®) for infection prophylaxis and inflammation control after cataract surgery with intraocular lens implan...

Descripción completa

Detalles Bibliográficos
Autores principales: da Cunha, Patrícia Abreu Ferreira, Shinzato, Flavio Araujo, Tecchio, Geraldine Trevisan, La Porta Weber, Sarah, Brasil, Alexandre, Avakian, Amaryllis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3674263/
https://www.ncbi.nlm.nih.gov/pubmed/23778476
http://dx.doi.org/10.6061/clinics/2013(06)18
_version_ 1782272337147592704
author da Cunha, Patrícia Abreu Ferreira
Shinzato, Flavio Araujo
Tecchio, Geraldine Trevisan
La Porta Weber, Sarah
Brasil, Alexandre
Avakian, Amaryllis
author_facet da Cunha, Patrícia Abreu Ferreira
Shinzato, Flavio Araujo
Tecchio, Geraldine Trevisan
La Porta Weber, Sarah
Brasil, Alexandre
Avakian, Amaryllis
author_sort da Cunha, Patrícia Abreu Ferreira
collection PubMed
description OBJECTIVE: To compare the efficacy and tolerability of a fixed combination of 0.3% gatifloxacin and 1% prednisolone (Zypred®) versus the individual components used separately (Zymar® and Predfort®) for infection prophylaxis and inflammation control after cataract surgery with intraocular lens implantation. METHODS: A prospective, randomized, double-blind, parallel-group study of 108 patients who underwent phacoemulsification and intraocular lens implantation was conducted. After random assignment, 47 eyes received the fixed combination of topical 0.3% gatifloxacin/1% prednisolone drops, and 61 eyes received the same doses of the individual components as separate solutions four times a day for 15 days. Baseline and postoperative assessments were made on postoperative days 1, 7, 15, and 20. RESULTS: All objective (best corrected visual acuity, sign of active ocular inflammation, central and incisional corneal edema, the number of cells per high-power field in the anterior chamber, and intraocular pressure) and subjective (eye pain, photophobia, burning sensation, itching, and foreign body sensation) criteria of efficacy were similar in both groups, with no significant differences. Group I included 47 eyes that received the fixed combination of gatifloxacin/prednisolone acetate eye drops and a placebo eye drop solution. Group II included 61 eyes that were treated with 0.3% gatifloxacin and 1% prednisolone acetate eye drops separately. The intraocular pressure was slightly higher in Group II (p<0.05). CONCLUSION: Treatment with the fixed-dose combination of gatifloxacin/prednisolone eye drops was as effective as the non-fixed combination in preventing infection and controlling inflammation after phacoemulsification and intraocular lens implantation.
format Online
Article
Text
id pubmed-3674263
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
record_format MEDLINE/PubMed
spelling pubmed-36742632013-06-07 Efficacy and tolerability of a gatifloxacin/prednisolone acetate fixed combination for topical prophylaxis and control of inflammation in phacoemulsification: a 20-day-double-blind comparison to its individual components da Cunha, Patrícia Abreu Ferreira Shinzato, Flavio Araujo Tecchio, Geraldine Trevisan La Porta Weber, Sarah Brasil, Alexandre Avakian, Amaryllis Clinics (Sao Paulo) Clinical Science OBJECTIVE: To compare the efficacy and tolerability of a fixed combination of 0.3% gatifloxacin and 1% prednisolone (Zypred®) versus the individual components used separately (Zymar® and Predfort®) for infection prophylaxis and inflammation control after cataract surgery with intraocular lens implantation. METHODS: A prospective, randomized, double-blind, parallel-group study of 108 patients who underwent phacoemulsification and intraocular lens implantation was conducted. After random assignment, 47 eyes received the fixed combination of topical 0.3% gatifloxacin/1% prednisolone drops, and 61 eyes received the same doses of the individual components as separate solutions four times a day for 15 days. Baseline and postoperative assessments were made on postoperative days 1, 7, 15, and 20. RESULTS: All objective (best corrected visual acuity, sign of active ocular inflammation, central and incisional corneal edema, the number of cells per high-power field in the anterior chamber, and intraocular pressure) and subjective (eye pain, photophobia, burning sensation, itching, and foreign body sensation) criteria of efficacy were similar in both groups, with no significant differences. Group I included 47 eyes that received the fixed combination of gatifloxacin/prednisolone acetate eye drops and a placebo eye drop solution. Group II included 61 eyes that were treated with 0.3% gatifloxacin and 1% prednisolone acetate eye drops separately. The intraocular pressure was slightly higher in Group II (p<0.05). CONCLUSION: Treatment with the fixed-dose combination of gatifloxacin/prednisolone eye drops was as effective as the non-fixed combination in preventing infection and controlling inflammation after phacoemulsification and intraocular lens implantation. Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo 2013-06 /pmc/articles/PMC3674263/ /pubmed/23778476 http://dx.doi.org/10.6061/clinics/2013(06)18 Text en Copyright © 2013 Hospital das Clínicas da FMUSP http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Science
da Cunha, Patrícia Abreu Ferreira
Shinzato, Flavio Araujo
Tecchio, Geraldine Trevisan
La Porta Weber, Sarah
Brasil, Alexandre
Avakian, Amaryllis
Efficacy and tolerability of a gatifloxacin/prednisolone acetate fixed combination for topical prophylaxis and control of inflammation in phacoemulsification: a 20-day-double-blind comparison to its individual components
title Efficacy and tolerability of a gatifloxacin/prednisolone acetate fixed combination for topical prophylaxis and control of inflammation in phacoemulsification: a 20-day-double-blind comparison to its individual components
title_full Efficacy and tolerability of a gatifloxacin/prednisolone acetate fixed combination for topical prophylaxis and control of inflammation in phacoemulsification: a 20-day-double-blind comparison to its individual components
title_fullStr Efficacy and tolerability of a gatifloxacin/prednisolone acetate fixed combination for topical prophylaxis and control of inflammation in phacoemulsification: a 20-day-double-blind comparison to its individual components
title_full_unstemmed Efficacy and tolerability of a gatifloxacin/prednisolone acetate fixed combination for topical prophylaxis and control of inflammation in phacoemulsification: a 20-day-double-blind comparison to its individual components
title_short Efficacy and tolerability of a gatifloxacin/prednisolone acetate fixed combination for topical prophylaxis and control of inflammation in phacoemulsification: a 20-day-double-blind comparison to its individual components
title_sort efficacy and tolerability of a gatifloxacin/prednisolone acetate fixed combination for topical prophylaxis and control of inflammation in phacoemulsification: a 20-day-double-blind comparison to its individual components
topic Clinical Science
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3674263/
https://www.ncbi.nlm.nih.gov/pubmed/23778476
http://dx.doi.org/10.6061/clinics/2013(06)18
work_keys_str_mv AT dacunhapatriciaabreuferreira efficacyandtolerabilityofagatifloxacinprednisoloneacetatefixedcombinationfortopicalprophylaxisandcontrolofinflammationinphacoemulsificationa20daydoubleblindcomparisontoitsindividualcomponents
AT shinzatoflavioaraujo efficacyandtolerabilityofagatifloxacinprednisoloneacetatefixedcombinationfortopicalprophylaxisandcontrolofinflammationinphacoemulsificationa20daydoubleblindcomparisontoitsindividualcomponents
AT tecchiogeraldinetrevisan efficacyandtolerabilityofagatifloxacinprednisoloneacetatefixedcombinationfortopicalprophylaxisandcontrolofinflammationinphacoemulsificationa20daydoubleblindcomparisontoitsindividualcomponents
AT laportawebersarah efficacyandtolerabilityofagatifloxacinprednisoloneacetatefixedcombinationfortopicalprophylaxisandcontrolofinflammationinphacoemulsificationa20daydoubleblindcomparisontoitsindividualcomponents
AT brasilalexandre efficacyandtolerabilityofagatifloxacinprednisoloneacetatefixedcombinationfortopicalprophylaxisandcontrolofinflammationinphacoemulsificationa20daydoubleblindcomparisontoitsindividualcomponents
AT avakianamaryllis efficacyandtolerabilityofagatifloxacinprednisoloneacetatefixedcombinationfortopicalprophylaxisandcontrolofinflammationinphacoemulsificationa20daydoubleblindcomparisontoitsindividualcomponents